Mendelspod Podcast cover art

All Episodes

Mendelspod Podcast — 558 episodes

#
Title
1

Agilent and Oxford Nanopore Discuss Bringing Long Reads to the Clinic with a Customer

2

Liquid Biopsy for the Tumor Microenvironment: with Vince Miller and Mirna Jarosz

3

Can Liquid Biopsy Transform Chronic Disease? Hamed Amini and Soheil Damangir of Hepta

4

The UAE’s Big Bet on Genomic Medicine with Mohamed Alameri and Albarah El-Khani

5

Ryan Flynn of Harvard on Non-Coding RNA

6

Gary Schroth on Connecting Cellular Behavior to the Transcriptome

7

Two-Thirds of High-Risk Breast Cancer Patients May Avoid Chemotherapy According to Veracyte Data Presented at ASCO

8

Building the Diagnostic Layer of Modern Cancer Care with Rita Shaknovich and Karina Kulangara of Agilent

9

Mapping the Multi-Omic Era with Eric Green of Illumina

10

Inside Proteomics at Thermo Fisher with Yan Zhang

11

Separating Epigenetic Signals Improves Early Cancer Detection with Rob Osborne, Biomodal

12

Digital Controls for Cancer Drug Trials? Irina Babina, Concr

13

Solexa Co-Inventor Shankar Balasubramanian on Six-Base Sequencing and What's Next in Genomics

14

The Next Frontier in Biology: Physics? Erdinc Sezgin of the Karolinska Institute

15

The Case for a 6-Base Genome with Peter Fromen, CEO of Biomodal

16

The Eligible But Under-Tested: Genomic Medicine in 2026 with Damon Hostin, Illumina

17

Spatial Transcriptomics Is Changing How We Do Biology: Fei Chen, The Broad Institute

18

Beyond GLP-1: Why Peptides Are Back at the Center of Drug Discovery with Charlie Johannes and Tomi Sawyer

19

From the Archives: Inventor Mark Kokoris Debuts Roche’s New SBX Sequencer

20

Why Do Some Animals Live Ten Times Longer? Pursuing the Science of Aging with Steve Austad

21

MRD Testing: From Residual Disease to Real Decisions with Chris Hourigan and Gary Pestano

22

Early vs Late Recurrence: How Multimodal AI Is Changing Breast Cancer Prognosis with George Sledge, Caris Life Sciences

23

The Dark Genome with Author Sudhakaran Prabakaran

24

Illumina's New Mapped Read Technology Provides Insights into Rare Disease: Stephen Kingsmore, Olivia Kim-McManus and Ali Crawford

25

CareDx’s Second Act with CEO John Hanna

26

Inside GP2: Building a Global Genetic Map of Parkinson’s with Andrew Singleton and Ignacio Mata

27

A Simple Sponge, a Big Shift in Cell Therapy with Yev Brudno, UNC

28

How Cellanome Is Changing the Way We Study Cell Function with Matthew Spitzer and Pier Federico Gherardini

29

From Hereditary Risk to Residual Disease: Natera’s Integrated Vision for Precision Oncology with Adam ElNaggar, MD

30

The Rise of Geroscience with Alan Landay and Tom Blackwell, UTMB

31

Unlocking the RNA Revolution: How Self-Replicating RNA Could Transform Vaccines and Therapeutics with Andrew Geall, Replicate Bioscience

32

From Targets to Hits: The Emerging AI Ecosystem in Drug Discovery with Aqib Hasnain, Mithrl and Cheng Hu, Technetium Therapeutics

33

Most Popular Show of 2025: How Certis Is Rewriting Cancer Models with CEO Peter Ellman

34

Building the Front-End for Every Sequencer with Volta Labs CEO Udayan Umapathi

35

A New Foundational Platform for Biology: Cellanome’s Debut with CEO Omead Ostadan

36

The Best of Times, the Worst of Times: Former NHGRI Director Eric Green on a Shaken NIH and Surging Genomic Science

37

From the Archives: Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz

38

Petter Brodin of Karolinska: How Spatial Interactomics Could Transform Autoimmune Therapy

39

From GWAS to EWAS: Chirag Patel and and Gary Miller on the Rise of Exposomics

40

Agilent Partners with PacBio to Speed Adoption of Long Reads into Diagnostic Testing

41

How AI Is Doing Science with Vivek Adarsh, CEO of Mithrl

42

Inventor Mark Kokoris on Roche’s New Sequencing by Expansion

43

From Brewing Sake to Brewing Science: Takara Bio’s Bold New Chapter with CSO Andrew Farmer

44

How Pathologists Can Lead in Precision Medicine with David Braxton

45

From DNA to Proteins: Illumina Makes Its Proteomics Play - with Krishna Morampudi

46

Theranos Had the Vision. Truvian Has the Execution. Our Chat with CEO Jay Srinivasan

47

Physicians Don't Want a Laundry List of Genes says Premal Shah, CEO of Myome

48

The Customer Case for iconPCR with Stefan Green and Yann Jouvenot

49

Alex Dickinson on Long Read Sequencing, Multi Omics, and the Next Frontier in Genomics

50

Rapid Answers for Rare Disease: Katherine Stueland on GeneDx’s Mission

51

Moran Snir's Vision for Making Genomic Care Routine across the U.S.

52

How Certis Is Rewriting Cancer Models with CEO Peter Ellman

53

Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing

54

Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz

55

Bodour Salhia and Danielle Goldberg: Rethinking Cancer Research with Illumina's 5-Base Solution

56

Reinventing PCR: Pranav Patel, N6 Tec

57

Making Whole Genome Sequencing the Universal Genetic Test - with David Ledbetter, Pediatric Rare Disease Institute, FSU

58

Remembering Atul Butte with Marina Sirota, Chirag Patel and Mike Snyder

59

The Age of Digital Pathology with Andy Beck, PathAI

60

What’s New for Regulatory Informatics in the Age of AI? Not Much—And That’s the Point with Raju Rayavarapu of DNAnexus

61

From Illumina to Advocacy: Mike Kreitzinger on the Future of Clinical Genomics

62

Amplifying the Expert: Jing Gao on Illumina's Connected Insights

63

The End of Animal Testing? Vivodyne Scales Human Tissue with CEO Andrei Georgescu

64

How Liquid Biopsy Is Becoming Standard of Care with Rita Shaknovich, CMO, Agilent

65

Tracking GMOs in the Gene Editing Era: Frédéric Debode on the Science of GMO Detection

66

From Discovery to Translation: Bruker's Bold New Play in Spatial with Joe Beechem and Oliver Braubach

67

Tagomics Wins NHS Grant, Unveils De-Methylation Platform for Early Cancer Testing with Rob Neely, CSO

68

From Paris to the Pentagon: Sophie Peresson Maps Biosecurity’s New Landscape

69

From Mitochondria to Protein Degradation: Mike Kiebish on BPGbio’s "Biology First" Vision

70

The Grammar of RNA: Gavin Knott on Gene Editing and Structural Biology in the Age of AI

71

The Third Way: Christian Schafmeister’s Spiroligomer Revolution

72

Can Math and AI Replace Some Biology in Drug Discovery? with Aridni Shah, Immunito AI

73

$10 Genome, $8 Coffee: Rethinking the Economics of Life Science Tools with Stephane Budel, DeciBio

74

Quantum Scale: A New Era for Single-Cell Analysis with Giovanna Prout

75

Building Intuition at the Nanoscale: Steve McCloskey of Nanome on the VR Future of Science

76

Beyond the $100 Genome--the Everyday Sequencing Revolution You Missed: Mark Budde, Plasmidsaurus

77

What Next for LDTs? A Conversation with Sarah Overton of Velsera

78

AI’s Quiet Revolution in the Pharma Supply Chain with Chris Petersen, Scientist.com

79

We've Been Misclassifying Childhood AML for Years: Jeffery Klco, St. Jude's

80

Aaron Viny: A 21-Year Leukemia Survivor on the Frontlines of Epigenetic Cancer Research

81

Toward Disease Sub-typing with Ben Busby, DNAnexus

82

Synthetic Biology Ready for Its ChatGPT Moment: A Preview of SynBioBeta 2025 with John Cumbers

83

Beyond the Parts List: Chris Mason and Simon Fredriksson on Mapping the Immune System in Space and Cancer with Cell Surface Proteomics

84

DNA Is Still Where It's At: Christian Henry, CEO of PacBio, on Watershed Year in 2024

85

A New Sequencing Technology Has Entered the World: Keith Robison Reviews AGBT and New Tech in our Annual Sequencing--er, Multi-Omics Show

86

Unlocking the Future of Forensic Genetics with Mirna Ghemrawi

87

Public Science in Peril: Hank Greely of Stanford on Funding, Fishing, and the Fight for Knowledge

88

Breaking the ‘Undruggable’ Barrier with AI and Synthetic Biology: Eswar Iyer, CEO of Aikium

89

"They're not cutting a branch. They're cutting the whole tree." Laura Hercher Defends DEI in Genomic Research and Medicine

90

Early Detection for Lung Cancer with Susan Tousi, DELFI Diagnostics

91

Big RNA with Brendan Frey of Deep Genomics

92

Genome Informatics in the Age of AI With Ben Busby, DNAnexus

93

AI & the Future of Genetic Testing: Ezra Cohen, CMO of Tempus

94

PredxBio and the Promise of Spatially Intelligent Biology

95

Surprise: Our Most Popular Show of 2024 Was on Genomic AI

96

New Startup Launches Epigenetic Screening: Mohamad Takwa, CEO, Epigenica

97

AI Powered Multiomics: Joachim Schmid on Data Analysis at Illumina

98

Renowned GI Oncologist Discusses MRD Testing and the Future of Cancer Detection

99

Precision Medicine Then and Now: We Talk with the Retiring President of the Personalized Medicine Coalition, Ed Abrahams

100

MicroRNA: A New Era in Biomarker Discovery with Tim Williams and Paola Ulivi

101

Somatic Genomics: A Revolution in Biology with Jacob Rubens

102

Exploring the Future of Single Cell Technology with Mauro Muraro, CEO, Single Cell Discoveries

103

Grail and Verily Alum on Billion Dollar Startup Bringing AI to Drug Development: A Discussion with Vik Bajaj

104

Singular Genomics Introduces a Dual-Purpose Platform Capable of Both NGS and Spatial Multiomics: Drew Spaventa, CEO & Founder

105

The Evolving Future of Genetic Counseling with Ellen Matloff, CEO, MyGeneCounsel

106

As Sequencing Continues to Scale, Volta Labs Improves Sample Prep: Udayan Umapathi, CEO

107

What’s Next for Large-Scale Proteomics? With Chris Whelan, Janssen

108

Will this At-Home Blood Collection Device Transform Medicine? Ben Casavant, Tasso

109

Geneticist Kevin Mitchell Attempts to Naturalize Free Will in New Book

110

ctDNA Testing Could Lead to New Ways of Staging Cancer Patients, Says Ben Weinberg, MedStar Georgetown

111

14th Season Opener: Michael Levin on ‘The New Biology’

112

The Success of ctDNA Testing in Colorectal Cancer: Adham Jurdi, Natera

113

Henrik Zetterberg on the Current Excitement Around Alzheimer’s Research

114

The Reboot of Consumer Genomics? with Kian Sadeghi, Nucleus Genomics

115

From Geospatial to Biospatial: Avi Veidman of Nucleai

116

New Proteomics Technology Brings Unprecedented Sensitivity and Scale: Yuling Luo, CEO, Alamar Bio

117

Diagnostic Trends in 2024 with Mara Aspinall, Illumina Ventures

118

The Actionable Epigenome with Bret Barnes, Illumina

119

Not All Prenatal Screens Are the Same: Jennifer Hoskovec, Billion to One

120

Harvard's Marc Lipsitch on the New White House Policy Regulating Risky Pathogen Research

121

Liquid Biopsy Goes Beyond Cancer: Diana Abdueva and Maggie Louie, Aqtual

122

Cell Therapy Will Transform Medicine as We Know It, Says Jason Bock, CTMC

123

Two Industry Leaders on Dealing with the Growing Complexity of Genomic Cancer Data

124

Single Cell Spatial Proteomics with Filip Karlsson, Pixelgen

125

The Precision Medicine Optimist: Damon Hostin, Illumina

126

An Ethics First Approach to Genetic Research and Drug Development with Sarah LeBaron von Baeyer

127

How Do You Train Genomics AI? On Natural Selection Itself, Says VP of Illumina’s AI Lab, Kyle Farh

128

The Pre-Symptomatic Space with Patrick Short, Sano Genetics

129

Systemwide Implementation of Precision Medicine at UCHealth with David Kao

130

Is this New Tech a Game Changer for Spatial Biology?

131

Synthetic Biology in 2024 with John Cumbers

132

Illumina Scales Variant Calling and Genome Interpretation to Improve Gap in Genetic Testing with Sam Strom

133

The Renaissance in DNA Synthesis Continues: Cosimo Ducani, CEO, Moligo

134

Jennifer Wipf of Ginkgo Bioworks on RNA Therapeutics and Cell Therapy

135

Precision Medicine for Dogs: Christina Lopes, OneHealth

136

Taking Gene Therapy to the Next Level: Rahul Kakkar of Tome

137

Christian Henry of PacBio on Long Reads at Scale, Next Moves

138

Robert Michel, Editor at The Dark Report, on Gap in Genetic Testing

139

Turning to Next Gen Proteomics for Novel Biomarkers: Jon Brudvig and Bruce Wilcox

140

What Have We Learned from the Brain Map Project So Far? with Tom Nowakowski, UCSF

141

Quality Healthcare Should Not Depend on Which Book Club You Attend, Karen Tumulty of the Washington Post

142

Real Probiotics: Colleen Cutcliffe, CEO, Pendulum Therapeutics

143

Todd Druley of Mission Bio on Single Cell Multi-Omics

144

Kevin Davies on Gene Therapy in 2023

145

History and State of Proteomics 2023 with John Yates

146

New Philosophy of Biology Series on PBS: A Preview with Host Robert Lawrence Kuhn

147

Mapping the Meta Proteome: John Shon, CTO, Serimmune

148

Supercharged Killer Cells Effective Against Alzheimer’s: Paul Song, CEO, NKGen Biotech

149

Chris Hall and Rich Chen of Personalis on Next Gen MRD Testing

150

State of Sequencing 2023: Shawn Baker and Keith Robison

151

Newborn Sequencing 2023 Part II: What Evidence Is Enough?

152

Lincoln Nadauld on the State of Precision Medicine in 2023

153

Nothing Is "Undruggable:" Alex Federation, CEO, Talus Bio

154

Mass Spec Advances in a New Age of Proteomics: Rosy Lee, Thermo Fisher Scientific

155

This Is Very Cool: Treating Cancer with Sound

156

The Future of Clinical Proteomics with Jenny Van Eyk and Daniel Hornburg

157

Elinor Karlsson on Darwin’s Ark

158

Long DNA for Difficult Applications: Dan Lin-Arlow, CEO, Ansa Biotech

159

Next Gen CRISPR Therapies with Trevor Martin, CEO of Mammoth Biosciences

160

13th Season Opener: Mike Snyder on Microsampling and Multi-Omic Profiling

161

Gene Patent Decision at 10 Years, State of Genetic Testing with Ellen Matloff, My Gene Counsel

162

Proteomics Bigger than Genomics, It’s Just Taking Time, Says Jeff Hawkins, CEO, Quantum-SI

163

Biden, AI, and DeSci: John Cumbers Previews SynBioBeta 2023

164

Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study

165

Is This New Platform an Answer to the Reproducibility Crisis? with Guy Rohkin

166

Elegen Pioneers Long DNA Subindustry with CEO Matt Hill

167

Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More

168

3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics

169

New Spatial Company Maps Cell Surface Proteome without Imaging

170

John Greally on His Latest Review of Epigenomics

171

President of ASHG on Eugenics Apology, Diversity Initiative

172

23andMe Launches New Personalized Healthcare Initiative with Amy Sturm

173

Converting Digital to Biological: John Gill, Telesis Bio

174

50% Not Tested: Precision Oncology with Jerome Madison, Invitae

175

Paul Freemont on Synthetic Biology in the UK

176

The Bioengineered Hangover Cure: Changing the Conversation around GMOs with Zack Abbott of ZBiotics

177

Lance Baldo of Freenome on their Approach to Early Cancer Detection

178

Mara Aspinall on COVID

179

Terry Lo of Vizgen on Spatial Genomics

180

Proteomics at Scale Empowers Genomics in New Ways: Dale Yuzuki, Olink

181

A New Tool in the Genomics Kit with Ivan Liachko of Phase Genomics

182

Paul Kruszka of GeneDx/Sema4 on Groundbreaking Newborn Sequencing Study

183

Is PGx Having a Moment? Kristine Ashcraft, Invitae

184

Christian Henry on Revio, Onso and the New Vision at PacBio

185

The Revolution in Single Molecule Sequencing Continues: Vijay Ramani, UCSF

186

Will Hwang of Mass General on Discovery of Novel Pancreatic Cancer Cell Subtype

187

Going Beyond Time Barriers: Arutha Kulasinghe on the Power of New Spatial Biology Tools

188

Invitae’s Data Manager, Farid Vij, on New Genome Management Platform

189

Satellite Bio out with a New Tissue Based Approach to Regenerative Medicine

190

We Have to Get Sequencing Back to Moore’s Law: Gilad Almogy, Ultima Genomics

191

RNA Therapeutics: A New Paradigm for Drug Development? Tim Mercer, BASE Lab, U of Queensland

192

The System is Working. We Need More Engagement, Says ClinVar Champion Heidi Rehm of Mass General in Her Update on the State of Genomic Medicine in 2022

193

The Promise of Exosomes Now Realized, Says Paul Billings, CEO, Biological Dynamics

194

Lee Cronin on Origin of Life, Genomics, Aliens and More

195

Eric Green on the Future of the NHGRI

196

5-Base Sequencing: Jonas Korlach and Tomi Pastinen

197

More Cancer Patients Die from Infections than Cancer, Says Alec Ford, CEO of Karius

198

Some of the Lowest Hanging Fruits in Precision Medicine: Michelle Whirl-Carrillo on Pharmacogenomics

199

John Nelson of GE Research Talks Vaccines on Demand, Enzymatic Synthesis, and the Era of Writing DNA

200

A New Generation Comfortable Doing a Thousand Things at a Time Is Reinventing Life Science Says Joe Beechem of NanoString

201

Enabling a New Age of Unbiased Proteomics Discovery: Omid Farokhzad, Seer Inc.

202

The Rise of MRD Testing and the Field of Fragmentomics with Sugganth Daniel, Invitae

203

The Invention of Enzymatic DNA Synthesis with Sylvain Gariel, DNA Script

204

Akoya Biosciences Launches New Integrated Spatial Platform: Our First Interview with CEO Brian McKelligon

205

Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity

206

Twist Bioscience: A New Kind of DNA Synthesis Company

207

Going High Resolution with 10X Genomics: Michael Schnall-Levin

208

George Church and Ben Lamm on the Launch of Colossal Biosciences

209

We Might Be the Comeback Kids of the Universe: Chris Mason on His Plan for the Next 500 Years

210

Invitae and PacBio CEOs Share Details of Clinical Sequencing Partnership

211

Building on the Knowledge Base of Developer Community, LuminexPLORE Lab Offers Custom Insights: Jackie Surls, Director

212

DNA Script Takes DNA Synthesis Back to the Bench with Enzymatic Tech: Thomas Ybert, CEO

213

Tumor Evolution in Context with Christina Curtis

214

The History of mRNA Vaccines with Elie Dolgin

215

Hundreds of Thousands of Biological Molecules Undiscovered in Plant Chemical Space Says Founder of New Drug Discovery Company

216

Quantitative Pathology with David Rimm, Yale

217

The State of Comprehensive Genomic Profiling at One of America’s Largest Health Systems with Carlo Bifulco

218

Inside the World of Genome Engineering at Amyris with Kirsten Benjamin, VP of R&D

219

Clinical Genetics 2021 Highlights: Laura Hercher, Host of the Beagle Landed Podcast

220

A New Way to Phenotype Life: Chris Mason Talks Spatial Biology, His New Book

221

The Impact of Spatial Technology on Childhood Cancers with David Steffin, Texas Children's

222

Robert Green: Newborn Sequencing Is the Goal Here in the U.S.

223

The Studies Are In—Optical Mapping Can Replace Traditional Cytogenetics Tests

224

Amy Sturm of Geisinger on FH Testing and New Implementation Science

225

Out of the Reductionist Trap: Brad Gray of NanoString on Spatial Biology

226

Precision Oncology at the Community Level with Lee Schwartzberg

227

Daniel Kraft on the Digitome and COVID

228

Orchid Health Is 1st in the World to Offer Whole Genome Couple's Report

229

PacBio and Labcorp Team Up on a Global Pan-Pathogen Surveillance Network

230

Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix

231

A Liquid Biopsy Technology that Doesn't Degrade the Sample: Raj Krishnan of Biological Dynamics

232

The Future of Big Biology: Bionano at AGBT

233

Playing Catch Up--Viral Surveillance in the U.S. with Will Lee of Helix

234

The Coronavirus, A Year On with Carl Zimmer

235

Spatial Biology Enables The Cancer Immunome Project

236

The CRISPR Saga with Kevin Davies

237

PacBio’s Never Been Stronger: New CEO, Christian Henry, Shares His Vision

238

Keith Robison on the State of Sequencing: 2020 Edition

239

Halloween with Nathan and Laura: The Spooky and Creepy of Genomics

240

When and Why Whole Genome Sequencing Should Be Standard of Care: Stephen Kingsmore of Rady Children’s

241

Limited Genetic Diversity Affects Us All

242

Genomics England Making Significant Strides in System Built on Trust in NHS

243

September 2020 Review with Nathan and Laura: Vaccine Choice, Dwarfism, Research Volunteerism

244

Bob Nussbaum on the State of Genetic Testing: 2020 Edition

245

SynBioBeta 2020 with John Cumbers

246

Mapping Intracellular Context: Garry Nolan on Spatial Biology

247

August 2020 Review: Radical Shift on LDT Policy, First Pan-Cancer Liquid Biopsies, and New Alzheimer’s Test

248

Using CRISPR Genome Editing Tools, Willow Biosciences out with First Synthetic Cannabinoid

249

The Pros and Cons of Expanded Carrier Screening with Mary Norton, UCSF

250

Is This A Unique Time for Science? We Ask Sci-fi Writer Kim Stanley Robinson

251

May 2020 with Nathan and Laura: Vaccine News, Notre Dame Argument, COVID Genetic Targets

252

Matt Loose on "Read Until" or Adaptive Sequencing

253

The Current State of Coronavirus Vaccines with Jeff Stein, Cidara Therapeutics

254

April 2020 Review with Nathan and Laura: Ioannidis Scandal, Antibody Testing, Ethics Questions

255

Lab Director Speaks to the Challenges of COVID-19 Testing: Elaine Lyon, HudsonAlpha

256

FDA in the Time of Coronavirus: Understanding the New VALID Act with Turna Ray, GenomeWeb

257

March 2020 Review with Nathan & Laura: Corona Gets Personal, Where Are the Tests?, the VALID Act, Some non-Corona Science

258

90% Go Undiagnosed, Says Geisinger’s Amy Sturm of FH Patients

259

Lisa Alderson on Her Telegenetics Firm, Genome Medical, Also Speaks to the DTC Downturn

260

February 2020 Review with Nathan and Laura: Coronavirus, Medicare for All, and Live from AGBT

261

Pouria Sanae on the DTC Slowdown and His New Precision Health Testing Platform

262

January 2020 Review: Genetic Counselors vs ACMG, 23andMe Layoffs, Privacy

263

End-of-Decade Review, What's Next? with Nathan and Laura

264

Ewan Birney on Race, UK Genomics

265

November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost

266

Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing

267

The Gene Edited Babies Saga - A Year Later with Hank Greely

268

Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae

269

The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

270

October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG

271

Should We Increase Panel Testing for All Breast Cancer Patients?

272

Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution

273

Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

274

Karen Miga on the Next Era of Genomics

275

September 2019 Review with Nathan and Laura: Same-Sex Genetics, Mosquitos, and Another DTC Scandal

276

We Can See Tumor Heterogeneity. Now What? We Ask Cathy Smith, UCSF

277

Hallelujah! A Universal Flu Preventative and Therapy with Jeff Stein, Cidara

278

'The Movement:' John Cumbers Previews the Rapidly Growing SynBioBeta 2019

279

Anya Prince on Our Current Vulnerability to Genetic Discrimination

280

Do Long Reads Hold Answers for Alzheimer’s? with Mark Ebbert, Mayo

281

With Nanopore Sensing Beyond Sequencing, Ontera Takes 'Lab' to the Field

282

Mark Chaisson on Two New Structural Variation Papers

283

Early Cancer Detection: Is This Company Ahead of Grail?

284

June 2019 Review with Nathan and Laura: Gene Patents, Grail, Dr. Lynch

285

Should Genomic Screening Be Standard of Care? with Adam Buchanan, Geisinger

286

May 2019 Review with Nathan and Laura: Gene Therapies, DTC Shifts, Gender and Sports

287

Toward the Human Pan Genome with Adam Phillippy, NHGRI

288

Laura Hercher on the DTC Genetic Testing Landscape

289

Arcadia Biosciences Pivots to Bring Us Non-GMO, High Fiber GoodWheat and Better Cannabis

290

April 2019 Review with Nathan and Laura: uBiome Raided by FBI, PRS for Obesity, and a Gene Therapy Cure

291

The Era of the Social Genome with Rodrigo Martinez, Veritas Genetics

292

Reassessing Alzheimer’s with Larry Goldstein, UCSD

293

Family Surprises Care of the Home DNA Test with Brianne Kirkpatrick

294

March 2019 with Nathan and Laura: Old Envelopes, Wooly Mammoth DNA, and the Night King

295

Single Cell Analysis Shows Important New Detail in Key Clinical Study of AML: Koichi Takahashi, MD Anderson

296

Science Communication in a Post Fact World with Erik Clausen

297

February 2019 Review with Nathan and Laura: Family Surprises, IQ Profiling, and Chinese Surveillance

298

Heretic No Longer? Meet Michael Joyner, Precision Medicine’s Critic-in-Chief

299

The Internet of Biology Revolution-For Real This Time, with Brett Goldsmith, Cardea

300

January 2019 Review with Nathan and Laura: Cloning, CRISPRing, DTC, and Paleogenomic Overreach

301

Cara O'Neill of the Cure Sanfilippo Foundation Tells Her Story

302

PregSource: The NIH’s Crowdsourcing Project for Pregnancy Data with Caroline Signore

303

Meet Christian, Janos, and the New World of 3D Oncology

304

Has Computational Modeling for Cancer Genomics "Arrived?" with Shirley Liu, Dana Farber

305

Amy Harmon of the NYT on Race & Genetics, Women in Science

306

CRISPR or Not, You Can't Genetically Enhance Humans, Says Sci-Fi Author Kim Stanley Robinson

307

The New World of Infectious Disease Diagnosis: Out in the Field with David Hong of Karius

308

California Life Science Industry Steps to New Heights - the 2019 Edition with Sara Radcliffe

309

Nathan and Laura on CRISPRed Babies and Other November 2018 Stories

310

Ellen Matloff on a New Digital Genetic Counseling Product for DTC Customers

311

Connecting the Dots for a Community of Rare Disease Patients: Terri Klein, MPS Society

312

Keith Robison and Shawn Baker on Illumina Buyout of PacBio

313

October 2018 Review with Nathan and Laura: ASHG Does Race, Parents Do Gene Therapy, Unsung Demons

314

A Point-of-Care CBC Test Based on a Few Drops of Blood—Is This the Real Thing? with Danny Levner, Sight Diagnostics

315

It’s a Gold Rush in Single Cell Genomics, Says Joachim Schultze, U of Bonn

316

A Market Solution for Biospecimen Quality Standards with Matt McLoughlin, Scientist.com

317

September 2018 with Nathan and Laura: Studying the Same Genes and the Matt Fender Story

318

Single Cell Sequencing Tailor Made for Nephrology, Says Vivek Bhalla, Stanford

319

It’s the Social Factors, Stupid! Lisa Suennen on Healthcare, Her Career, Digital Health Investing, and . . . Just Being Herself

320

Concerned About DTC Test Quality? Ask Two Questions, Says Daryl Pritchard, PMC

321

August 2018 Review with Nathan and Laura: The polygenic month

322

An International Perspective on How to Improve Biobanking with Kirstin Goldring

323

A Seqster Preview with Founder Ardy Arianpour

324

Detective Stories from the Genomic War Room with Ramesh Hariharan

325

Should Biobanking Come Under CLIA? Shannon McCall, Duke

326

Pharma Stepping Up, Footing the Bill for Genetic Testing & Counseling: Jordanna Mora, Alnylam

327

Are We Asking Too Much of Genomics in Cancer Research? Tony Letai, Dana Farber

328

I Won’t Rest Until We Have Quality Standards in Place for Biospecimens: Carolyn Compton, ASU

329

May 2018 with Nathan and Laura: The Free Exome, California Database, and Mosaicism

330

Has Diagnostic Testing Plateaued? Alka Chaubey, Greenwood Genetic Center

331

A New Way for DTC? Nathan Pearson, Root Deep Insight

332

Genetic Testing in the Age of Trump: Hank Greely, Stanford

333

Genetic Testing is Dead, Long Live Genetic Testing: Sean George of Invitae

334

April 2018 with Nathan and Laura: Golden State Killer and the Cancer Prediction Space

335

Liquid Biopsy for Infectious Disease with Mickey Kertesz, Karius

336

Nanopore Sequencing and the Future of Cancer Research with Chia-Lin Wei, JAX

337

A New Method for Long Reads: Hanlee Ji of Stanford on Cancer Genomics Tech 2018

338

March 2018 in Genomics with Nathan & Laura: DTC BRCA and Revisiting All of Us

339

With More Tools in the Box, Lon Cardon Says We’re in a New Age of Drug Development

340

Personalized Medicine in the Trump Era with Edward Abrahams

341

Eric Schadt and Sema4 Try the Consumer Model with Newborn Screening Panel

342

February 2018 in Genomics with Nathan & Laura: 23andMe Goes for the Gold, Trump Year One

343

State of Sequencing 2018 with Keith Robison, Omics! Omics! Blogger

344

Direct RNA-Seq Project Shows Nanopore Sequencing Can Reveal New Insights into Basic Biology: Winston Timp, JHU

345

January 2018 Review Show with Nathan and Laura: CRISPR vs The Immune System, Biotech Math, and MinION's Big Test

346

Going Beyond the Liver with RNAi: Chris Anzalone of Arrowhead Pharma

347

Vice Chancellor Keith Yamamoto on UCSF’s Role in Medicine Today

348

The Global Business of Reproductive Genetic Testing with Gary Harton, Igenomix

349

The State of Genomics 2018 with Nathan, Laura, and Misha

350

Sharon Begley of STAT News

351

A New “Middle Way” for Genomics, with Physical Chemist, Yuval Ebenstein

352

Sara Demy on Biotech CEOs

353

November 2017 with Nathan and Laura: The Stem Cell Story We’ve All Been Waiting For and a Sea Change for DTC Testing

354

Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine

355

Immuno Oncology 2017: Looking Back, Looking Forward with Rachel Laing and Olivier Lesueur

356

Huh? 30 Million Americans Have a Rare Disease? Howard Jacob on the State of Clinical Sequencing

357

With their Own Manufacturing Facility, Seattle Children’s Goes Big into CAR-T, Rare Disease

358

With Immuno Oncology Comes a New Focus on Rare Cells

359

We've Become Too Single Variant Centric, Says Deanna Church on Genome Analysis

360

Clinicians Show High Demand for Single Cell Sequencing, Says Bobby Sebra of Mt. Sinai

361

September 2017 with Nathan and Laura: Venter Blunder, RNAi Returns, and Monthly Science Moments

362

Charting the Dark Matter of Cancer Genomes with Jim Broach

363

Why Childhood Cancers Need Their Own Gene Panel: Tim Triche

364

Exploring the Exome and the Future of Genomics with Jay Shendure

365

August 2017 Review with Nathan and Laura: CAR-T Cashes In, Embryos Edited in US, and the Invitae Incident

366

The First In-Human Gene Editing Trial in the U.S. - And It’s Not with CRISPR

367

Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer

368

Making Genetic Testing Mainstream Medicine with Sean George, Invitae

369

Need Better Standards for Your Clinical Assays? NIST Can Help

370

Turning on Your DNA with Justin Kao, Helix

371

Will This New Nano Technology Be the Microarray of Genomic Structural Variation? Barrett Bready, Nabsys

372

George Church on What Comes After CRISPR

373

Is CRISPR Controversy Science or Spin? June 2017 Review with Nathan and Laura

374

We Need a Google Maps for Metagenomics, Says Rob Knight, UCSD

375

Move Over PDL1: New Test Combo Adds RNAseq to Better Track Immune Escape

376

The Last Major Disease To Be Studied? Ron Davis of Stanford Thinks So

377

On Bioinformatics Data Sharing and Collaboration: Andrew Carroll, DNAnexus

378

Grail Merger, Genomic Autopsies, Overtreatment Alarm, and Controversy at Ancestry.com: May 2017 Review with Nathan and Laura

379

Is Population Medicine Failing Us? Michel Accad

380

Deep Omics Profiler, Mike Snyder, Now Turns to Wearables

381

Over $1 Billion Invested this Past Year: Synthetic Biology in 2017 with John Cumbers

382

Green Light for DTC, Blood Mammograms, and Ancient DNA: April 2017 with Nathan and Laura

383

With 50 Million Users, Is Academia.edu Speeding Up Science?

384

How to Improve Lab Tests in the Absence of FDA Regulation?

385

Known for Medical Devices, 116 Yr Old BD Makes a Bold Move in Genomics

386

Proposed NIH Cuts, Undermining GINA, and Game Changing Drugs: March 2017 with Nathan and Laura

387

Art in the Lab (Falling in Love with Bacteria)

388

Flint Whistleblower Says Today's Science Is to Blame for Its Own Lack of Public Trust

389

The Story of Geisinger and Doing Genomic Medicine at the Right Pace

390

In-Situ Sequencing, CRISPR Patents, and Racist Milk Drinkers: February 2017 with Nathan and Laura

391

New Pocket Size Nanopore Device Could Revolutionize Diagnostic and Other Testing

392

By Changing a Basic Lab Step, Acoustic Liquid Transfer Having a Broad Impact

393

Many Biologists Today Don’t Have Enough Computer Science to Use the Databases

394

Cardiologists Love Genomics: Euan Ashley, Stanford

395

Scientists vs Trump: January 2017 with Nathan and Laura

396

Want to Stop Smoking? Start with Epigenetic Biomarker that Tells Doc the Truth

397

When an Exome Test Is Part of the Therapy and Not a Diagnostic: John West on Personalis and Personalized Cancer Vaccines

398

People Told Us It Was Impossible: UCSC’s Mark Akeson on Nanopore Sequencing

399

When Long Reads are Double the Price of Short Reads, Short Reads Are Dead, Says Evan Eichler

400

Genomics in 2016: Nathan and Laura Name Their Top Stories

401

Hank Greely on “The End of Sex" and Other Stuff

402

How to Scale Cancer Genomics, with Marco Marra, UBC

403

What Does the Election Mean for Genomics? November 2016 with Nathan and Laura

404

The Saga Continues: Ethan Perlstein, Indie Scientist, Part 3

405

Biomarker Panel to Predict Type 1 Diabetes

406

Can You Name the World’s Largest Single Disease Research Charity?

407

Why Diversity Is the Only Path Forward: Sarah Tishkoff on African Genomics

408

October 2016 with Nathan and Laura

409

We’re Over Halfway There: Baylor's Richard Gibbs on Clinical Genetics

410

With FDA Guidance on LDTs Still Not Out, What Are Labs Doing?

411

Reference Genome Making Major Strides in Ethnic Diversity, Says Valerie Schneider, NCBI

412

September 2016 with Nathan and Laura

413

Luke Timmerman on His New Biography of Lee Hood

414

How Personalized is Personalized Medicine? Krister Wennerberg on FIMM’s Individualized Systems Medicine

415

Digital PCR Opens Up New Liquid Biopsy Opportunity in Melanoma Treatment: David Polsky, NYU

416

Erica Ramos on Her Pioneering Role as Genetic Counselor for Industry

417

August 2016 with Nathan and Laura

418

A Maniacal Commitment to Science: Peering into Regeneron’s Genetics Center with Jeff Reid

419

The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 2

420

The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 1

421

A Precision Medicine Platform Comes of Age: Jonathan Hirsch, Syapse

422

FDA’s Liz Mansfield on New NGS Guidances

423

How Is the Brexit Impacting Genomics? with Clare Turnbull and Hadyn Parry

424

It’s Not Really Bulls and Bears: John Carroll on His New Gig, the Brexit, and a New Metaphor for the Market

425

June 2016 with Nathan and Laura: GMO Labeling, Misspelling CRISPR, Sequenom Patent Loss, SmidgIon

426

Know Then Thyself: Kari Stefansson, deCODE genetics

427

Sequenom Patent Loss a Threat to Personalized Medicine, Says Kevin Noonan

428

Bringing Home Some Diagnostics Gold: Brad Gray, NanoString Show How It’s Done

429

Mukherjee Mess-up, the Secret Harvard Meeting, and Success in Gene Therapy: May 2016 with Nathan and Laura

430

When Do We Move to Population Based Cancer Screening for Those with High Genetic Risk? Josh Schiffman, U of U

431

The Solid Future of Liquid Biopsies with Michael Nall, Biocept

432

Genomics Is Oversubscribed, Says Creator of BLAST

433

With 10K Genomes Sequenced, Genomics England in High Gear: Clare Turnbull, Clinical Lead

434

April 2016 with Nathan and Laura: Big Money, More CRISPR Studies, Genomic Superheroes, and a Pot Chaser

435

A Sneak Peek into the Future of Clinical Genomics with Ben Solomon, Inova

436

Preprints and the Future of Science Publishing with Jason Hoyt, PeerJ

437

Flipping Drug Development Upside Down: Niven Narain, BERG Health

438

March 2016 with Nathan and Laura: Genomic Jenga and the Creator, the Anti-Abortion Lobby and Genetic Testing, and Theranos, Again

439

Medicine and the Limits of Science with Michel Accad, MD

440

How Good are Linked Reads? Serge Saxonov, 10X Genomics

441

A Home Run on the First Hit: PacBio’s Jonas Korlach

442

Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level

443

February 2016: Mosquitos, Preprints, and that Rocking White House Summit

444

BioNano Genomics Stakes Out Sequencing Territory as They Discover Lots of De Novo Variants in Reference Genome Projects

445

Is Oxitec Ready to Scale as Governments Seek Options to Control the Zika Virus?

446

Human Genome Turns 15: Mike Hunkapiller

447

January 2016: Landergate, Grail, and Cancer Moonshot

448

Frontiers of Sequencing: Putting Long Reads and Graph Assemblies to Work

449

Why Drugs Are Priced So High and Diagnostics So Low

450

Who Is John Ioannidis?

451

Cancer: Year in Review 2015 with Anna Barker

452

Sci-Fi Author Kim Stanley Robinson Talks Life Science 2015

453

Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler

454

Genomics and the Cloud Going Through “a Second Puberty,” says AWS’ Angel Pizarro

455

Hot Biotech Market Neglects Stem Cell Therapies, Says CIRM's Neil Littman

456

The Future of Diagnostics Reimbursement with Bruce Quinn

457

Framingham for the Modern Era: Josie Briggs on the Precision Medicine Initiative

458

Do Alternate Proposals to Regulate LDTs Stand a Chance?

459

Does the Reproducibility Project in Cancer Biology Offer a Model for a New Kind of Science Auditing?

460

After CMS Announcement, Peter Maag and CareDx Fight for Life

461

The Goal Is De Novo Assembly in the Clinic, Says Jim Lupski, Baylor

462

Cliff Reid Says New Supersequencer Leads the Pack for High Throughput Clinical Sequencing

463

Defending the Value of Biotech Innovation in California: Sara Radcliffe, CLSA

464

Long Read Sequencing Dramatically Improves Blood Matching: Steven Marsh, Anthony Nolan Institute

465

The World of DIY Genomics with K T Pickard

466

Sequencing in Space: Chris Mason, Cornell

467

Is the Future of Biology a Return to Chemistry? Carolyn Bertozzi, Stanford

468

Going Beyond the $1,000 Genome with Mark Gerstein

469

Creating the Foundation of Genomics: Marc Salit, NIST

470

Still Unhappy with FDA’s Plan to Regulate LDTs, Professional Lab Groups Go Direct to the Senate

471

A Diagnostic Success Story with Alka Chaubey, Greenwood Genetic Center

472

With Two New Easy-to-Use Sequencing Instruments, Thermo Readies for Primetime in the Clinic

473

Here's Looking at Euclid

474

Is This the Future of Clinical Trials for Cancer? Stanley Hamilton on the NCI’s New MATCH Trial

475

Brian Kennedy and Aubrey de Grey on their Converging Approaches to Aging Research

476

The Business of Aging and Three Reasons Why the FDA Drug Approval Rate Is So High

477

New York Genome Center’s Nathan Pearson on Public Outreach for Genomics

478

Tim Triche on Using Arrays for Cancer Research

479

Thermo’s Chris Linthwaite on Sequencing the Ebola Virus and the Future of Public Health

480

A Tool to Strengthen the Voice of Science in Online Journalism

481

Father of Child with Rare Disease Says Science Equals Medicine

482

Bina CEO Details Secret to Success in NGS Informatics

483

Cancer Researcher Tim Triche on the Staying Power of Microarrays

484

Want Answers? Look to the Non-Coding Region of the Genome, Says Cancer Researcher, Tim Triche

485

Ivan Oransky on Today's Retraction Boom

486

Genomics-Palooza, Diagnostics Fraud, and Biblical Prophets on the Future of Biotech

487

Ethical Issues around Editing Human Germline for the Future. Today It's about Plants and Animals, Says NYU's Art Caplan

488

We Got Research, PCSK9 Inhibitors, and Clinical Trials for Religion

489

The Multi-Platform Approach to Clinical Sequencing with Bobby Sebra, Icahn School

490

So That Happened, The Mad Genius, and Selling SynBio

491

Summer Genomics Festival, the Other Sports Genes, and Brain Surgery for Fruit Flies

492

The Sports Genes with Jeremy Koenig, Athletigen

493

Woodstock for Genomics? Richard Lumb and Carl Smith on this Month’s Festival

494

Geneticists Anonymous, the Sad State of Science Journalism, and New Kids on the Helix

495

The 9 Billion People Problem: Rod Wing on Plant Genomics

496

Should We Hold Back the Reins on Biotechnology? with Chris Gunter

497

Are We Ready to Trust Liquid Biopsies? with Milena Cankovic, Henry Ford Hospital

498

Gene and Tonic: Boxing for Cancer, Dubious Correlations, and When Should a Researcher Retire

499

New Patient Focused Genome Magazine Signing up Many Doctors Too

500

Gene and Tonic: The Decline of Pseudoscience, An Atheist for President, and What to Do with a Sexist Reviewer

501

Gene and Tonic: Sexism in Science, How to Spend an NIH Budget Increase, How Not to Spend It

502

Participation in Genomics Research a 21st Century Public Good, Says Paul Billings of Omicia

503

Gene and Tonic: Competition for 23andMe, Four Tips for Attending AACR 2015, and "Swab Stories"

504

Improving the Backbone of Clinical Genomics : Valerie Schneider, NCBI

505

Gene and Tonic: The ACA Turns Five, Ten Reasons to Have Your Genome Sequenced, and Humbled by the Ancients

506

Behind the Sequencing Bench with Dale Yuzuki

507

Gene and Tonic: The Tenth Commandment of Science, Icelandic Treasure, and TechBio Babies

508

It’s Pretty Bad: Andy Brooks of RUCDR on Sample Quality

509

Knowing More about What We Don’t Know: John McPherson on Cancer Genomics

510

Gene and Tonic: The iWatch and Research Kit, 23andMe Goes for the Big Time, No Spaceship

511

In Partnership with IBM’s Watson, Pathway Genomics Reinvents Itself

512

Affymetrix CEO, Frank Witney, on Arrays in the Age of Sequencing

513

Gene & Tonic: Disruption in Sequencing, Scientist Politicians, Some Cool Synbio

514

Changing the World with Color Changing Flowers

515

Cancer Researcher at Mayo Says Illumina Platform Maxing Out, Looks to BGI/Complete

516

Returning to Old Biotech Model, OncoMed Boasts of Seven Drugs in Clinical Trials by Mid 2015

517

Cutting through the Hype in Healthcare Innovation with David Shaywitz and Lisa Suennen

518

A Call to Consumers to Lead the Shift in Healthcare: Sharon Terry, Genetic Alliance

519

In Autoimmune Disease, Finding Clarity Beyond the Genome: Stefan Muellner, Protagen

520

Myriad Settlements Mark End of an Era: Antoinette Konski on Gene Patents

521

David Schwartz on the Future of Sequencing

522

Not a Stenographer to Power: Luke Timmerman and the New 'Timmerman Report'

523

FDA Will Take Time to Digest Comments on LDT Guidance, Says Liz Mansfield

524

Future of Personalized Medicine at Stake, says Amy Miller of PMC about LDT Regulation

525

'A Good Year' with John LaMattina

526

An Exciting Time for Mass Spec: Paul Beresford, Biodesix

527

Current Version of LDT Draft Guidance Means Much Fewer and Lower Quality Tests for Patients, Says Elaine Lyon of ARUP

528

The Sad State of Biospecimen Science with David Rimm, Yale

529

Cancer 2014: The Year in Review with Anna Barker

530

Faces of Leadership in Diagnostics: Surbhi Sarna

531

Historic Consensus Reached on Biospecimen Standards: Carolyn Compton, NBDA

532

Setting Better Expectations for Genomic Medicine: Geoff Ginsburg, Duke University

533

Test Driving Genomic Medicine: Thomas Quertermous, Stanford

534

The Silicon Valley Fantasy Trip: Sci-fi Author Kim Stanley Robinson Talks Life Science

535

Faces of Leadership in Diagnostics: Mara Aspinall

536

The Daunting Task of Managing Biospecimens at the World's Largest CRO: Diane Farhi, Quintiles

537

Janet Woodcock, FDA, on Biomarker Development and the Future of Clinical Trials

538

Biosampling Basics with Scott Jewell, Van Andel Institute

539

Faces of Leadership in Diagnostics: Bonnie Anderson, Veracyte

540

Biotech’s Gentleman Lawyer: Alan Mendelson

541

The Open Secret about the HER2 Assay with Jim Vaught

542

What a Physicist Can Tell Us about Cancer

543

'Moving Target Science:' Jonathan Brody on Pancreatic Cancer

544

The Progress of Clinical Genomics in Sweden with Ulf Gyllensten

545

Proteins Are Where It's At: Chip Petricoin, George Mason University

546

After a Decade on the Sidelines, Gene Myers Back into Sequencing, Excited about Long Reads

547

The Story of Aubrey de Grey and How the Study of Aging Became Mainstream

548

#ScienceHack with Connor Dickie, Synbiota

549

What Translational Gap? Michael Pishvaian on Advances in Tumor Profiling

550

A Dangerous Book? Science Historian Nathaniel Comfort Discusses “A Troublesome Inheritance”

551

Eric Schadt on Long Read Sequencing and Clinical Genomics

552

George Church at 60

553

Major Sequencing Projects Should Be Done with Long Reads, Says Dan Geraghty

554

Test Driving Illumina's X Ten with Shawn Baker, AllSeq

555

Short Read Sequencing Not Up to the Task of Characterizing Transcriptome Says Mike Snyder of Stanford

556

U.K. Life Science Update with Eliot Forster, MedCity

557

Paperwork, Not Algorithms the Biggest Challenge for Large Bioinformatics Projects, Says David Haussler, UCSC

558

Big Pharma Does Some Farming: Pearl Huang, GSK